Modulation of protein aggregation by polyethylene glycol conjugation: GCSF as a case study

Protein Science

Volumn 15, Issue 5, 2006, Pages 1063-1075

  Rajan, Rahul S ^a   Li, Tiansheng ^a   Aras, Mohini ^b   Sloey, Christopher ^a   Sutherland, Weston ^a   Arai, Hiromi ^c   Briddell, Robert ^a   Kinstler, Olaf ^a   Lueras, Alexis M K ^a   Zhang, Yu ^a   Yeghnazar, Heather ^a   Treuheit, Michael ^a   Brems, David N ^a  

^a AMGEN INC   (United States)

^b University of California   (United States)

^c CALIFORNIA STATE UNIVERSITY CHANNEL ISLANDS   (United States)

Author keywords

GCSF; Polyethylene glycol; Protein aggregation; Protein stability; Solubility

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; MACROGOL; PROTEIN;

AMINO TERMINAL SEQUENCE; ANALYTIC METHOD; ARTICLE; CHEMICAL BOND; CONFORMATIONAL TRANSITION; CONJUGATION; PH MEASUREMENT; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN CONFORMATION; PROTEIN SECONDARY STRUCTURE; PROTEIN STABILITY; SOLUBILITY; SOLVATION; TEMPERATURE DEPENDENCE;

COPPER; GRANULOCYTE COLONY-STIMULATING FACTOR; KINETICS; POLYETHYLENE GLYCOLS; PRECIPITATION; PROTEIN STRUCTURE, SECONDARY; PROTEINS; SOLUBILITY; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33646154457     PISSN: 09618368     EISSN: 1469896X     Source Type: Journal    
DOI: 10.1110/ps.052004006     Document Type: Article

References (47)

1. Al-Azzam, W., Pastrana, E.A., King, B., Mendez, J., and Griebenow, K. 2005. Effect of the covalent modification of horseradish peroxidase with poly (ethylene glycol) on the activity and stability upon encapsulation in polyester microspheres. J. Pharm. Sci. 94: 1808-1819.
2. Arakawa, T., Horan, T.P., Leong, K., Prestrelski, S.J., Narhi, L.O., and Hu, S. 1995. Structure and activity of granulocyte colony-stimulating factor derived from CHO cells containing cDNA coding for alternatively spliced sequences. Arch. Biochem. Biophys. 316: 285-289.
3. Bence, N.F., Sampath, R., and Kopito, R.R. 2001. Impairment of the ubiquitin proteasome system by protein aggregation. Science 292: 1552-1555.
4. Bishop, B., Koay, D.C., Sartorelli, A.C., and Regan, L. 2001. Reengineering granulocyte colony-stimulating factor for enhanced stability. J. Biol. Chem. 276: 33465-33470.
5. Brems, D.N. 2002. The kinetics of G-CSF folding. Protein Sci. 11: 2504-2511.
6. Buchsel, P.C., Forgey, A., Grape, F.B., and Hamann, S.S. 2002. Granulocyte macrophage colony-stimulating factor: Current practice and novel approaches. Clin. J. Oncol. Nurs. 6: 198-205.
7. Canet, D., Sunde, M., Last, A.M., Miranker, A., Spencer, A., Robinson, C.V., and Dobson, C.M. 1999. Mechanistic studies of the folding of human lysozyme and the origin of amyloidogenic behavior in its disease-related variants. Biochemistry 38: 6419-6427.
8. Chaiken, I.M. and Williams, W.V. 1996. Identifying structure-function relationships in four-helix bundle cytokines: Towards de novo mimetics design. Trends Biotechnol. 14: 369-375.
9. Chen, S., Ferrone, F.A., and Wetzel, R. 2002. Huntington's disease age-of-onset linked to polyglutamine aggregation nucleation. Proc. Natl. Acad. Sci. 99: 11884-11889.
10. Clark, E.D. 2001. Protein refolding for industrial processes. Curr. Opin. Biotechnol. 12: 202-207.
11. Cleland, J.L. and Jones, A.J. 1996. Stable formulations of recombinant human growth hormone and interferon-gamma for microencapsulation in biodegradable microspheres. Pharm. Res. 13: 1464-1475.
12. Fink, A.L. 1998. Protein aggregation: Folding aggregates, inclusion bodies and amyloid. Fold. Des. 3: R9-R23.
13. Foguel, D., Robinson, C.R., Caetano de Sousa Jr., P., Silva, J.L., and Robinson, A.S. 1999. Hydrostatic pressure rescues native protein from aggregates. Biotechnol. Bioeng. 63: 552-558.
14. Havel, H.A., Kauffman, E.W., Plaisted, S.M., and Brems, D.N. 1998. Reversible self-association of bovine growth hormone during equilibrium unfolding. Biochemistry 25: 6533-6538.
15. Herman, A.C., Boone, T.C., and Lu, H.S. 1996. Characterization, formulation, and stability of Neupogen (Filgrastim), a recombinant human granulocytecolony stimulating factor. In Formulation, characterization and stability of protein drugs (ed. R. Pearlman and Y.J. Wang), pp. 303-328. Plenum Press, New York.
16. Hermeling, S., Crommelin, D.J., Schellekens, H., and Jiskoot, W. 2004. Structure-immunogenicity relationships of therapeutic proteins. Pharm. Res. 21: 897-903.
17. Hill, C.P., Osslund, T.D., and Eisenberg, D. 1993. The structure of granulocytecolony-stimulating factor and its relationship to other growth factors. Proc. Natl. Acad. Sci. 90: 5167-5171.
18. Hora, M.S., Rana, R.K., Nunberg, J.H., Tice, T.R., Gilley, R.M., and Hudson, M.E. 1990. Controlled release of interleukin-2 from biodegradable microspheres. Biotechnology (N.Y.) 8: 755-758.
19. Jensen, P.Y., Bonander, N., Horn, N., Turner, Z., and Farver, O. 1999. Expression, purification and copper-binding studies for the first metalbinding domain of Menkes protein. Eur. J. Biochem. 264: 890-896.
20. Katre, N.V. 1990. Immunogenicity of recombinant IL-2 modified by covalent attachment of polyethylene glycol. J. Immunol. 144: 209-213.
21. Kerwin, B.A., Chang, B.S., Gregg, C.V., Gonneli, M., Li, T., and Stambini, G.B. 2002. Interactions between PEG and type I soluble tumor necrosis factor receptor: Modulation by pH and by PEGylation at the N terminus. Protein Sci. 11: 1825-1833.
22. Kim, J.J. and Park, K. 2001. Glucose-binding property of pegylated concanavalin A. Pharm. Res. 18: 794-799.
23. Kinstler, O.B., Brems, D.N., Lauren, S.L., Paige, A.G., Hamburger, J.B., and Treuheit, M.J. 1996. Characterization and stability of N-terminally PEGylated rhG-CSF. Pharm. Res. 13: 996-1002.
24. Kinstler, O.B., Molineux, G., Treuheit, M., Ladd, D., and Gegg, C. 2002. Characterization and stability of N-terminally PEGylated rhG-CSF. Adv. Drug Deliv. Rev. 54: 477-485.
25. Kolvenbach, C.G., Narhi, L.O., Philo, J.S., Li, T., Zhang, M., and Arakawa, T. 1997. Granulocyte-colony stimulating factor maintains a thermally stable, compact, partially folded structure at pH 2. J. Pept. Res. 50: 310-318.
26. Krebs, M.R., Morozova-Roche, L.A., Daniel, K., Robinson, C.V., and Dobson, C.M. 2004. Observation of sequence specificity in the seeding of protein amyloid fibrils. Protein Sci. 13: 1933-1938.
27. Krishnan, S., Chi, E.Y., Webb, J.N., Chang, B.S., Shan, D., Goldenberg, M., Manning, M.C., Randolph, T.W., and Carpenter, J.F. 2002. Aggregation of granulocyte colony stimulating factor under physiological conditions: Characterization and thermodynamic inhibition. Biochemistry 41: 6422-6431.
28. Leo, A.J. 1976. Dependence of hydrophobicity of apolar molecules on their molecular volume. J. Med. Chem. 19: 611-615.
29. Li, J., Zhu, M., Manning-Bog, A.B., Di Monte, D.A., and Fink, A.L. 2004. Dopamine and L-dopa disaggregate amyloid fibrils: Implications for Parkinson's and Alzheimer's disease. FASEB J. 18: 962-964.
30. Lovejoy, B., Cascio, D., and Eisenberg, D. 1993. Crystal structure of canine and bovine granulocyte-colony stimulating factor (G-CSF). J. Mol. Biol. 234: 640-653.
31. Lu, H.S., Fausset, P.R., Narhi, L.O., Horan, T., Shingawa, T., Shimamoto, G., and Boone, T.C. 1999. Chemical modification and site-directed mutagenesis of methionine residues in recombinant human granulocyte colony-stimulating factor: Effect on stability and biological activity. Arch. Biochem. Biophys. 362: 1-11.
32. Luo, P., Hayes, R.J., Chan, C., Stark, D.M., Hwang, M.Y., Jacinto, J.M., Juvvadi, P., Chung, H.S., Kundu, A., Ary, M.L., et al. 2002. Development of a cytokine analog with enhanced stability using computational ultrahigh throughput screening. Protein Sci. 11: 1218-1226.
33. Metcalf, D., Robb, L., Dunn, A.R., Mifsud, S., and DiRago, L. 1996. Role of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor in the development of an acute neutrophil inflammatory response in mice. Blood 88: 3755-3764.
34. Mitraki, A. and King, J. 1989. Amino acid substitutions influencing intracellular protein folding pathways. Biotechnology (N.Y.) 7: 690-697.
35. Mitraki, A., Fane, B., Haase-Pettingell, C., Sturtevant, J., and King, J. 1991. Global suppression of protein folding defects and inclusion body formation. Science 253: 54-58.
36. Molineux, G. 2002. Pegylation: Engineering improved pharmaceuticals for enhanced therapy. Cancer Treat. Rev. Suppl A: 13-16.
37. Plakoutsi, G., Bemporad, F., Calamai, M., Taddei, N., Dobson, C.M., and Chiti, F. 2005. Evidence for a mechanism of amyloid formation involving molecular reorganization within native-like precursor aggregates. J. Mol. Biol. 351: 910-922.
38. Rajan, R.S. and Kopito, R.R. 2005. Suppression of wild-type rhodopsin maturation by mutants linked to autosomal dominant retinitis pigmentosa. J. Biol. Chem. 14: 1284-1291.
39. Rajan, R.S., Illing, M.E., Bence, N.F., and Kopito, R.R. 2001. Specificity in intracellular protein aggregation and inclusion body formation. Proc. Natl. Acad. Sci. 98: 13060-13065.
40. Raso, S.W., Abel, J., Barnes, J.M., Maloney, K.M., Pipes, G., Treuheit, M.J., King, J., and Brems, D.N. 2005. Aggregation of granulocyte-colony stimulating factor in vitro involves a conformationally altered monomeric state. Protein Sci. 14: 2246-2257.
41. Ratto, J.J., O'Conner, S.R., Distler, A.R., Wu, G.-M., Hummel, D., Treuheit, M.J., Herman, A.C., and Davis, J.M. 1997. Ethanol-sodium chloride-phosphate mobile phase for size-exclusion chromatography of poly(ethylene glycol) modified proteins. J. Chromatogr. A 763: 337-344.
42. Seefeldt, M.B., Kim, Y.S., Tolley, K.P., Seely, J., Carpenter, J.F., and Randolph, T.W. 2005. High pressure studies of aggregation of recombinant human interleukin-1 receptor antagonist: Thermodynamics, kinetics and application of accelerated formulation studies. Protein Sci. 14: 2258-2266.
43. Sinclair, A.M. and Elliott, S. 2005. Glycoengineering: The effect of glycosylation on the properties of therapeutic proteins. J. Pharm. Sci. 94: 1626-1635.
44. Speed, M.A., Wang, D.I., and King, J. 1996. Specific aggregation of partially folded polypeptide chains: The molecular basis of inclusion body composition. Nat. Biotechnol. 14: 1283-1287.
45. Stefani, M. and Dobson, C.M. 2003. Protein aggregation and aggregate toxicity: New insights into protein folding, misfolding diseases and biological evolution. J. Mol. Med. 81: 678-699.
46. Williams, A.D., Sega, M., Chen, M., Kheterpal, I., Geva, M., Berthelier, V., Kaleta, D.T., Cook, K.D., and Wetzel, R. 2005. Structural properties of Ab protofibrils stabilized by a small molecule. Proc. Natl. Acad. Sci. 102: 7115-7120.
47. Wimley, W.C., Creamer, T.P., and White, S.H. 1996. Solvation energies of amino acid side chains and backbone in a family of host-guest pentapeptides. Biochemistry 35: 5109-5124.